Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 6;6(1):e12016.
doi: 10.1002/trc2.12016. eCollection 2020.

Agitation and impulsivity in mid and late life as possible risk markers for incident dementia

Daniel R Bateman  1   2 , Sascha Gill  3 , Sophie Hu  4 , Erin D Foster  5   6 , Myuri T Ruthirakuhan  7   8 , Allis F Sellek  9 , Moyra E Mortby  10   11 , Veronika Matušková  12   13 , Kok Pin Ng  14 , Rawan M Tarawneh  15 , Yvonne Freund-Levi  16   17 , Sanjeev Kumar  18   19 , Serge Gauthier  20 , Paul B Rosenberg  21 , Fabricio Ferreira de Oliveira  22 , D P Devanand  23 , Clive Ballard  24 , Zahinoor Ismail  3   4   25 ; International Society to Advance Alzheimer's Research and Treatment (ISTAART), Neuropsychiatric Syndromes Professional Interest Area (NPS‐PIA)
Affiliations
Review

Agitation and impulsivity in mid and late life as possible risk markers for incident dementia

Daniel R Bateman et al. Alzheimers Dement (N Y). .

Abstract

To identify knowledge gaps regarding new-onset agitation and impulsivity prior to onset of cognitive impairment or dementia the International Society to Advance Alzheimer's Research and Treatment Neuropsychiatric Syndromes (NPS) Professional Interest Area conducted a scoping review. Extending a series of reviews exploring the pre-dementia risk syndrome Mild Behavioral Impairment (MBI), we focused on late-onset agitation and impulsivity (the MBI impulse dyscontrol domain) and risk of incident cognitive decline and dementia. This scoping review of agitation and impulsivity pre-dementia syndromes summarizes the current biomedical literature in terms of epidemiology, diagnosis and measurement, neurobiology, neuroimaging, biomarkers, course and prognosis, treatment, and ongoing clinical trials. Validations for pre-dementia scales such as the MBI Checklist, and incorporation into longitudinal and intervention trials, are needed to better understand impulse dyscontrol as a risk factor for mild cognitive impairment and dementia.

Keywords: MBI; agitation; disinhibition; impulse dyscontrol; impulsivity; mild behavioral impairment; pre‐dementia.

PubMed Disclaimer

Conflict of interest statement

Daniel Bateman: No conflicts of interest; Sascha Gill: No conflicts of interest; Sophie Hu: No conflicts of interest; Erin Foster: No conflicts of interest; Myuri Ruthirakuhan: No conflicts of interest; Allis Sellek: No conflicts of interest; Moyra Mortby: No conflicts of interest; Veronika Matušková: No conflicts of interest; Kok Pin Ng: No conflicts of interest; Rawan Tarawneh: No conflicts of interest; Yvonne Freund‐Levi: No conflicts of interest; Sanjeev Kumar: No conflicts of interest; Serge Gauthier serves as a member of scientific advisory board of Biogen, Lundbeck, and TauRx; Paul Rosenberg: No conflicts of interest; Fabricio Ferreira de Oliveira serves as a Healthcare Council Member for Gerson Lehrman Group; Devangere Devanand serves as a member of the scientific advisory board for Acadia, BXcel, Genentech, Grifols, and Corium; Clive Ballard reports receiving research grants from Acadia, and honoraria from Acadia, Lundbeck, Lilly, Otusaka, Orion, Bristol Myer Squibb, Esai, and Pfizer pharmaceutical companies; Zahinoor Ismail reports research funding, consulting fees, and honoraria from Janssen, Lundbeck, and Otsuka.

Figures

FIGURE 1
FIGURE 1
PRISMA Flow Diagram
FIGURE 2
FIGURE 2
Cytokine, Neuroendocrine and Immune System Associations with Agitation in Alzheimer's Disease
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psych‐Gerichtl Med. 1907;64:146‐148.
    1. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475‐1483. - PubMed
    1. Steinberg M, Shao H, Zandi P, et al. Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: The Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170‐177. - PMC - PubMed
    1. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14(7):561‐572. - PubMed
    1. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460‐465. - PMC - PubMed